RetinAI Medical AG (RetinAI) and Retina Consultants of America (RCA) are partnering to advance artificial intelligence (AI) applications in the analysis of clinical and imaging data in ophthalmology. The partnership leverages RetinAI’s digital health technologies and RCA’s large patient data network to create an extensive US-based database using Real-World Evidence (RWE). This database will benefit the healthcare industry by providing unique insights into drug efficacy, drug development processes, and patient care improvements.
Initially, this RWE database will be applied in retinal disease studies such as Age-related Macular Degeneration and Diabetic Retinopathy, among others, with a vision to extend into Cardiovascular and Neurodegenerative Diseases later. The companies plan to offer licensed access to the RWE data to interested stakeholders by Q4 2023.
To read more, click here.
What Experts Are Saying: “Through this partnership with RCA, we are revolutionizing the efficiency and robustness of making decisions around patient care, with an unprecedented scale of biomarker-driven insights from quality-driven, real-world data,” communicates Dr. Carlos Ciller, CEO of RetinAI, who then goes on to say, “This will enable an elevated level of target-based research and patient-centric care for continuous improvement to patient outcomes and the introduction of new precision-based medicines.”
[Source: PharmiWeb.com, July 25th, 2023]